Invion ( (AU:IVX) ) has provided an announcement.
Invion Limited has issued over two million fully paid ordinary shares, enhancing its financial position. The company is in preliminary discussions with RMW Cho Group Limited to potentially expand its Photosoft ™ technology rights to new territories or indications, though no binding agreement has been reached yet.
More about Invion
Invion is a life-science company focused on the global research and development of Photosoft ™ technology, primarily for cancer treatment. The company holds the license rights to this technology in Australia and New Zealand, with research and clinical trials funded by RMW Cho Group Limited.
Average Trading Volume: 110
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $6.13M
Find detailed analytics on IVX stock on TipRanks’ Stock Analysis page.